Vitiligo in multiple autoimmune disease: retrospective study of 11 cases and review of the literature.

被引:14
|
作者
Klisnick, A [1 ]
Schmidt, J [1 ]
Dupond, JL [1 ]
Bouchou, K [1 ]
Rousset, H [1 ]
Thieblot, P [1 ]
Humbert, P [1 ]
Vidal, E [1 ]
Aumaitre, O [1 ]
机构
[1] Hop Gabriel Montpied, Serv Med Interne, F-63003 Clermont Ferrand 1, France
来源
REVUE DE MEDECINE INTERNE | 1998年 / 19卷 / 05期
关键词
multiple autoimmune disease; vitiligo; autoimmune thyroid disease;
D O I
10.1016/S0248-8663(98)80107-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose. -The occurrence in the same patient of three or more autoimmune diseases defines multiple autoimmune disease. Multiple autoimmune disease is an unusual condition in which dermatological autoimmune diseases and especially vitiligo have an important place. Methods. -We examined retrospectively 11 cases of multiple autoimmune diseases associating vitiligo. We studied the clinical characteristics of vitiligo and those of the associated autoimmune disorders. Results. -Type III multiple autoimmune disease was diagnosed in all the 11 cases observed. Autoimmune vitiligo was the first autoimmune disorder observed in seven cases and was bilateral, symmetrical and acrofacial in eight cases. Autoimmune thyroid disorder was associated in ten cases. Our data confirms the important association between vitiligo and thyroid autoimmune disorders. Conclusion. -The predominant female ratio and the acrofacial topography of skin lesions could predict association with others autoimmune disorders in patients with vitiligo. (C) 1998, Elsevier, Paris.
引用
收藏
页码:348 / 352
页数:5
相关论文
共 50 条
  • [41] Bladder cancer and cyclophosphamide. Three cases and a review of the Literature.
    Alexandre, J
    Levy, V
    Hunault, M
    Bazarbachi, A
    Delmer, A
    Rio, B
    Zittoun, R
    BULLETIN DU CANCER, 1996, 83 (11) : 945 - 950
  • [42] Fibromyxoid tumour of the bladder:: report of 3 cases and review of the literature.
    de la Taille, A
    Thiounn, N
    Tissier, F
    Vieillefond, A
    Flam, T
    Zerbib, M
    Saighi, D
    Colla, S
    Debré, B
    PROGRES EN UROLOGIE, 2002, 12 (02): : 321 - 324
  • [43] The gastric leiomyosarcomas. Report of six cases with review of the literature.
    Krami, H
    Benzzoubeir, N
    Fadli, F
    Ouazzani, L
    Dafiri, N
    Ouazzani, H
    Souidine, F
    Hakam, Z
    Bennani, A
    ANNALES DE GASTROENTEROLOGIE ET D HEPATOLOGIE, 1998, 34 (01): : 35 - 39
  • [44] Primary dural lymphoma: a report of two cases with review of the literature.
    Benouaich, A
    Delord, JP
    Danjou, M
    Richaud, J
    Urocoste, E
    Soum, F
    Aziza, R
    Roche, H
    REVUE NEUROLOGIQUE, 2003, 159 (6-7) : 652 - 658
  • [45] Association between celiac disease and vitiligo: A review of the literature
    Zhang, Jing-Zhan
    Abudoureyimu, Dilinuer
    Wang, Man
    Yu, Shi-Rong
    Kang, Xiao-Jing
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (34) : 10430 - 10437
  • [46] Report of a case of fibrinous bronchitis, with a review of all cases in the literature.
    Bettmann, M
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1902, 123 : 304 - 329
  • [47] Stable dicentric chromosomes: Four new cases and a review of the literature.
    Lemyre, E
    Der Kaloustian, VM
    Duncan, AMV
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A169 - A169
  • [48] Association between celiac disease and vitiligo:A review of the literature
    Jing-Zhan Zhang
    Dilinuer Abudoureyimu
    Man Wang
    Shi-Rong Yu
    Xiao-Jing Kang
    World Journal of Clinical Cases, 2021, 9 (34) : 10430 - 10437
  • [49] A Review of the Vitiligo Literature to Standardize Expression of Disease Severity
    Renert-Yuval, Yael
    Desai, Seemal
    Huang, Victor
    Walsh, Samantha
    Rosmarin, David
    Silverberg, Nanette
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (10) : 842 - 846
  • [50] Autoimmune hepatitis associated with statins: a retrospective study of pharmacovigilance databases and review of the literature
    Pan, Chen
    Zhou, Xiaozhu
    Wang, Yu
    Wu, Yi
    Han, Qiang
    Cui, Xiangli
    EXPERT OPINION ON DRUG SAFETY, 2025,